Literature DB >> 15912969

Fontolizumab Protein Design Labs.

Francis J Dumont1.   

Abstract

Protein Design Labs is developing fontolizumab, a humanized anti-interferon gamma monoclonal antibody, for the potential treatment of autoimmune diseases. By February 2003, the company was actively seeking to outlicense the development and commercialization rights to fontolizumab outside of the US and Canada.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15912969

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies.

Authors:  Alexandra Belson; Tim Schmidt; Disala Fernando; Kelly Hardes; Nicola Scott; Sara Brett; Deborah Clark; João Joaquim Oliveira; Bill Davis; Simon McHugh; John Stone
Journal:  Inflamm Res       Date:  2016-03-11       Impact factor: 4.575

2.  Aplastic anemia: immunosuppressive therapy in 2010.

Authors:  Antonio M Risitano; Fabiana Perna
Journal:  Pediatr Rep       Date:  2011-06-22

3.  Construction, purification, and characterization of a chimeric TH1 antagonist.

Authors:  Iraldo Bello-Rivero; Yeny Torrez-Ruiz; Elizabeth Blanco-Garcés; Giselle Pentón-Rol; Osmani Fernández-Batista; Luís Javier-González; Haydee Gerónimo-Perez; Pedro López-Saura
Journal:  BMC Biotechnol       Date:  2006-05-22       Impact factor: 2.563
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.